ArticleNature materials2018
A facile approach to enhance antigen response for personalized cancer vaccination.
Article in Nature materials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
159 citing papers in PubMed, 1 synthesis or guideline pooled it, 391 citations in OpenAlex.
- Cell and tissue engineering in lymph nodes for cancer immunotherapy.Advanced drug delivery reviews · 2020Pooled it
- Low reactogenicity and high tumour antigen expression from mRNA-LNPs with membrane-destabilizing zwitterionic lipids.Nature biomedical engineering · 2026Article
- Immunotherapy Treatment of Colorectal Cancer and Lung Metastasis with Genetically Modified Outer Membrane Vesicles Delivering Poly-Neoepitopes in a Mouse Model.Applied biochemistry and biotechnology · 2026Article
- Engineered 3D-Lattice Microneedle Array Patches for Enhanced Nanovaccine Delivery to Dendritic Cells in Cancer Immunotherapy.ACS nano · 2026Article
- Cancer Therapy with Polymeric Nanocarriers and the Transition to Targeted Cancer Therapy: Advances and Future Directions.Pharmaceutical nanotechnology · 2026Review
- Controlling intracellular processing to enhance spherical nucleic acid immune stimulation.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Macroporous hydrogel-based mRNA cancer vaccine for in situ recruitment and modulation of dendritic cells.Acta biomaterialia · 2025Article
- Immunotherapy of Oncovirus-Induced Cancers: A Review on the Development and Efficacy of Targeted Vaccines.Vaccines · 2025Review
- Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines.Nano research · 2025Article
- Cell-Instructive Biomaterials with Native-Like Biochemical Complexity.Annual review of biomedical engineering · 2025Review
- Antigen/adjuvant-free liposome induces adjuvant effects for enhancing cancer immunotherapy.Exploration (Beijing, China) · 2025Article
- Microenvironment-based immunotherapy in oral cancer: a comprehensive review.Medical oncology (Northwood, London, England) · 2025Review
- Programmable Stapling Peptide Based on Sulfonium as Universal Vaccine Adjuvants for Multiple Types of Vaccines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Modulating Adjuvant Release Kinetics From Scaffold Vaccines to Tune Adaptive Immune Responses.Advanced healthcare materials · 2025Article
- Targeting vaccines to dendritic cells by mimicking the processing and presentation of antigens in xenotransplant rejection.Nature biomedical engineering · 2025Article
- Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells.Nature biomedical engineering · 2025Article
- Immune Cell Homing Hydrogels for Cancer Immunotherapy.Methods in molecular biology (Clifton, N.J.) · 2025Article
- pH-responsive nano-vaccine combined with anti-PD-1 antibodies for enhanced immunotherapy of breast cancer.Theranostics · 2025Article
- Enhanced Cancer Immunotherapy by Bacterial Cytoplasmic Membranes Coated Nanovaccines for Co-Delivery of Ovalbumin Antigen and Immune Adjuvants to Dendritic Cells in Lymph Nodes.International journal of nanomedicine · 2025Article
- A Purely Biomanufactured System for Delivering Nanoparticles and STING Agonists.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
99 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
Existing strategies to enhance peptide immunogenicity for cancer vaccination generally require direct peptide alteration, which, beyond practical issues, may impact peptide presentation and result in vaccine variability. Here, we report a simple adsorption approach using polyethyleneimine (PEI) in a mesoporous silica microrod (MSR) vaccine to enhance antigen immunogenicity. The MSR-PEI vaccine significantly enhanced host dendritic cell activation and T-cell response over the existing MSR vaccine and bolus vaccine formulations. Impressively, a single injection of the MSR-PEI vaccine using an E7 peptide completely eradicated large, established TC-1 tumours in about 80% of mice and generated immunological memory. When immunized with a pool of B16F10 or CT26 neoantigens, the MSR-PEI vaccine eradicated established lung metastases, controlled tumour growth and synergized with anti-CTLA4 therapy. Our findings from three independent tumour models suggest that the MSR-PEI vaccine approach may serve as a facile and powerful multi-antigen platform to enable robust personalized cancer vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.